Sangamo Therapeutics (SGMOQ) Liabilities and Shareholders Equity (2010 - 2025)

Sangamo Therapeutics has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $59.7 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 41.22% year-over-year to $59.7 million in Q4 2025; TTM through Dec 2025 was $332.1 million, a 23.63% decrease from a year earlier, with the FY2025 full-year figure at $59.7 million, down 41.22% from the prior year.
• Liabilities and Shareholders Equity was $59.7 million for Q4 2025 at Sangamo Therapeutics, down from $88.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $877.1 million in Q1 2021, with the low at $59.7 million in Q4 2025.
• Average Liabilities and Shareholders Equity over 5 years is $377.6 million, with a median of $272.4 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity soared 50.12% in 2021, then plunged 71.39% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $721.9 million in 2021, then decreased by 22.08% to $562.5 million in 2022, then tumbled by 70.61% to $165.3 million in 2023, then tumbled by 38.52% to $101.6 million in 2024, then slumped by 41.22% to $59.7 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $59.7 million (Q4 2025), $88.6 million (Q3 2025), and $97.6 million (Q2 2025), per Business Quant data.